<DOC>
	<DOCNO>NCT02578849</DOCNO>
	<brief_summary>The aim proposal include test hypothesis pathogenetic mechanism noradrenergic neurotransmission Parkinson 's disease vivo , use positron emission tomography patient early advance Parkinson 's disease without 3,4 L-dihydroxyphenylalanine ( L-DOPA ) - induced dyskinesia co-morbid depression , evaluation whether mechanism influence therapeutically . Hypotheses : 1 . The investigator argue release human cortical subcortical brain region norepinephrine ( NE ) derive metabolism exogenousL-DOPA great Parkinson 's disease patient L-DOPA- induce dyskinesia patient without complication . This hypothesis test measure antagonist [ 11C ] yohimbine bind alpha-2 adrenoceptors L-DOPA challenge . 2 . If , argue great rise norepinephrine , measure [ 11C ] yohimbine displacement L-DOPA challenge , result down-regulation loss norepinephrine transporter . This hypothesis test measure bind [ 11C ] MeNER , tracer norepinephrine transporter . 3 . If , investigator argue great decline [ 11C ] MeNER bind significantly correlate symptom Parkinson 's disease , proof patient severe loss noradrenergic terminal exhibit severe motor deficit .</brief_summary>
	<brief_title>Common Noradrenergic Mechanisms Parkinson´s Disease L-DOPA Induced Dyskinesia</brief_title>
	<detailed_description>Introduction : The major source NE central nervous system ( CNS ) locus coeruleus ( LC ) , send projection virtually part CNS , integrate cognitive autonomic function state arousal ( Sara SJ 2009 ) . With onset pathogenesis PD low brainstem , early symptoms PD include sleep disorder , cognitive deficit , autonomic dysfunction , may appear prior motor symptom PD , symptom link degeneration LC subsequent loss noradrenergic innervation peripheral central nervous system ( Rascol et al. , 2009 , Hawkes et al. , 2010 , Braak et al. , 2003 ) . The loss neuron LC exceed substantia nigra study ( Zarow et al . 2003 ) , also argue loss may relate symptom endogenous depression 40 % patient PD . In patient , severity motor symptom also may aggravate loss NE release dopamine ( DA ) fire dopaminergic neuron normally facilitate activation noradrenergic neuron . Lesion LC subsequent loss facilitation reduce nigrostriatal DA release . Similarly , lesion dopaminergic noradrenergic neuron induce severe motor deficit , compare lesion dopaminergic neuron alone ( Mavridis M et al. , 1999 ) . This relation suggest direct indirect role NE emergence severity motor non-motor symptom PD , include depression . The effect NE mediate stimulation three receptor subtypes alpha-1 , alpha-2 , ß . In proposed study , investigator focus alpha-2 ß-receptors . Of alpha-2 receptor , alpha2C subtype densely express structure basal ganglion therefore may mediate direct effect alpha-2 receptor motor behavior . However , contrast possible beneficial effect NE receptor activation brain region , non-physiological increase NE , L- DOPA administration , may elicit dyskinesia ( Buck et al. , 2010 ) fluctuation NE concentration region may contribute generation symptom depression ( Zarow et al . 2003 ) . Thus , several line evidence suggest loss NE may direct indirect role appearance severity motor non-motor symptom PD LIDs . Background : Noradrenergic treatment PD : The initial relief symptom PD offer DA agonist therapy complicate manifestation motor fluctuation , dyskinesia psychiatric side effect follow chronic treatment ( Ahlskog et al. , 2001 , Fox et al. , 2008 ) . The efficacy conventional DA agonist therapy reduce motor symptom PD relate ability restore lose dopaminergic innervation . However , recent evidence suggest activation non- dopaminergic transmitter system , include noradrenergic system may play important role mediate anti-parkinsonian effect L-DOPA . L-DOPA DA sequential precursor NE , excitation noradrenergic receptor follow L-DOPA administration may contribute anti-parkinsonian effect L-DOPA ( Schapira et al. , 2008 ) . Non-physiologically high release NE derive exogenous L-DOPA derive NE may contribute co-morbid depression LID . It suggest therapy maintain L-DOPA- induced activation NE receptor physiological level would reduce severity LID patient . However , underlie mechanism possible anti-parkinsonian dyskinetogenic role NE remain unresolved . In project , investigator propose identify mechanism NE convey beneficial adverse effect L-DOPA concert attempt help improve current treatment PD suggest therapy target non-physiological L- DOPA-induced activation NE receptors potential contributor LID . The investigator develop validate novel PET tracer use project . Carbon-11 label yohimbine alpha-2 adrenoceptor antagonist validate study PET pig ( Jakobsen et al. , 2006 , Landau et al . 2012 ) approve human use . To show bind [ 11C ] yohimbine sensitive endogenously release NE , investigator determine bind Vagus Nerve Stimulation minipigs vivo . This group researcher also develop selective NET ligand , [ 11C ] MeNER , clinical PET study Denmark . Patients PD age-matched healthy control undergo PET-scans above-mentioned tracer map pathological change noradrenergic transporter receptor in-vivo .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Yohimbine</mesh_term>
	<criteria>15 patient PD age 50 og 80 , Hoehn og Yahr stage 23 , never LDOPA induce dyskinesia . 15 patient PD age 50 og 80 år , Hoehn og Yahr stage 23 , establish LDOPA induce dyskinesia . 15 age match healthy control . Psychiatric neurological disease , relate Parkinson´s disease . Cancer malignant disease . Liver kidney disease . Alcohol substance abuse . Cardiac disease . Treatment antipsychotic antiepileptic medication affect noradrenergic system . Medicines treat Parkinson´s disease allow . Patients treat deep brain stimulation .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>